Company Oxford BioDynamics Plc

Equities

OBD

GB00BD5H8572

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:27 2024-04-26 am EDT			5-day change	1st Jan Change
8.1 ^GBX	-1.22%		-9.90%	-71.07%

Apr. 03	Oxford BioDynamics reaches "important milestone" with new laboratory	AN
Apr. 03	Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test	CI

Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patientâs therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.

Number of employees: 45

GBP in Million	2022	Weight	2023	Weight	Delta
Biomarker Research and Development 62.0 %	0	100.0 %	0	62.0 %	+105.19%
Proprietary Products 38.0 %	-	-	0	38.0 %	-

GBP in Million	2022	Weight	2023	Weight	Delta
United States 76.1 %	0	69.5 %	0	76.1 %	+262.62%
Rest of World 23.9 %	0	30.5 %	0	23.9 %	+159.57%

Managers	Title	Age	Since
Alexandre Akoulitchev FOU	Founder	62	07-04-22
Jon Burrows CEO	Chief Executive Officer	-	20-03-22
Paul Stockdale DFI	Director of Finance/CFO	-	17-09-14
Thomas Guiel COO	Chief Operating Officer	-	-
Bipin Patel LAW	General Counsel	-	19-12-31
Bartu Ahiska PRN	Corporate Officer/Principal	-	19-06-12
Ewan Hunter PRN	Corporate Officer/Principal	-	11-12-31

Members of the board	Title	Age	Since
Stephen Diggle BRD	Director/Board Member	60	16-10-03
David Holbrook BRD	Director/Board Member	63	19-04-04
Jon Burrows CEO	Chief Executive Officer	-	20-03-22
Paul Stockdale DFI	Director of Finance/CFO	-	17-09-14
Alexandre Akoulitchev FOU	Founder	62	07-04-22
Matthew Wakefield CHM	Chairman	65	20-12-13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	311,855,650	252,932,158 ( 81.11 %)	0	81.11 %

Name	Equities	%	Valuation
Stephen Diggle 14.66 %	29,653,978	14.66 %	4 M p
Vulpes Investment Management Pte Ltd. 14.01 %	28,333,756	14.01 %	3 M p
Unicorn Asset Management Ltd. 12.42 %	25,131,526	12.42 %	3 M p
Arbuthnot Latham & Co. Ltd. 9.126 %	18,462,000	9.126 %	2 M p
Seneca Partners 4.933 %	9,978,822	4.933 %	1 M p
Cantor Fitzgerald Europe 3.966 %	8,022,417	3.966 %	952 662 p
Investec Wealth & Investment Ltd. 3.618 %	7,319,886	3.618 %	869 236 p
Alexandre Akoulitchev 3.264 %	6,603,082	3.264 %	784 116 p
University of Oxford 2.830 %	5,724,476	2.830 %	679 782 p
KW Investment Management Ltd. 2.810 %	5,685,000	2.810 %	675 094 p

Oxford BioDynamics Plc

3140 Rowan Place John Smith Drive

OX4 2WB, Oxford

+44 1865 518 910

http://www.oxfordbiodynamics.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
OXFORD BIODYNAMICS PLC	-71.07%	20.41M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research